Search

Peptide

Reference library

Educational peptide reference — research use only.

Research & educational use only

For laboratory and educational research only. Not for human or veterinary consumption. This is not medical advice. Always follow applicable laws and consult qualified professionals.

The calculator performs unit math for research reference. It must not be used to plan or guide dosing in humans or animals. Verify all figures independently in your lab protocol.

HGH Fragment 176-191

A C-terminal hGH fragment studied in fat-metabolism research models.

Half-life (approx.)
~30 min (approx.)
Diluent
Bacteriostatic water (0.9% benzyl alcohol)
Common vials
2, 5 mg

Half-life figures are literature approximations for educational reference — not pharmacokinetic advice.

Overview

hGH fragment 176-191 represents the lipolytic region of growth hormone without the full GH diabetogenic activity in rodent studies. Often compared directly with AOD-9604 in published metabolic literature. Unmodified C-terminal hGH lipolytic fragment — parent sequence for AOD-9604 modifications.

Structure & identity

C-terminal 16 aa of hGH (176-191)

Sequence / structure
C-terminal 16 aa of hGH (176-191)

Mechanism

C-terminal hGH region promotes lipolysis without affecting glucose or IGF-1 levels. Lipolysis without hyperglycemia or IGF-1 elevation is the defining metabolic profile.

Studies & clinical programs

  • Lipolysis rodent models

    Published research models

    • Peer-reviewed literature documents endpoints under Lipolysis rodent models experimental designs.
  • Comparison with AOD-9604

    Published research models

    • Peer-reviewed literature documents endpoints under Comparison with AOD-9604 experimental designs.

Research models in literature

  • Lipolysis rodent models
  • Comparison with AOD-9604

Literature highlights

  • C-terminal hGH region promotes lipolysis without affecting glucose or IGF-1 in rodent models.
  • Frequently compared with AOD-9604 tyrosine-modified fragment in published literature.
  • β-adrenergic pathway involvement studied in adipocyte lipolysis assays.

Combination research notes

Published metabolic literature compares fragment 176-191 with AOD-9604 and MOTS-c.

Key targets & pathways

Lipolysisβ-adrenergic pathwaysβ-adrenergic sensitizationAdipose lipolysis

Research areas

LipolysishGH fragmentsMetabolic endpoints

Routes in research literature

Subcutaneous

Also known as

hGH fragAOD-related fragmentHGH Fragment 176-191hGH frag 176-191Fragment 176-191

Stability & storage phases

PhaseConditionGuidance
LyophilizedSealed vial, refrigerated (2–8 °C)Intact lyophilized cake or powder is typically stable for months to years per published stability data; protect from moisture, light, and repeated freeze-thaw of the dry vial.
ReconstitutedBacteriostatic water (0.9% benzyl alcohol), refrigeratedMost aqueous peptide solutions remain usable for approximately 2–4 weeks refrigerated; verify published stability data and label with reconstitution date.
Working aliquotsPre-drawn syringes or microtubes, frozen (−20 °C)Aliquot promptly after mixing to limit freeze-thaw cycles on the main vial; thaw once and use to reduce protease-mediated degradation.

Stability windows are formulation-dependent — verify published data and your lab SOP.

Reconstitution reference table

Vial (mg)Diluent (mL)mcg/mLUnits @ 100 mcgUnits @ 250 mcgUnits @ 500 mcg
221000.0102550
522500.041020

U-100 insulin syringe scale (100 units = 1 mL). Illustrative only — not dosing guidance.

Reconstitution steps

  1. Allow vial to reach room temperature (15–30 min)
  2. Swab rubber stopper with alcohol prep pad
  3. Draw calculated bacteriostatic water into syringe
  4. Inject diluent slowly down vial wall — do not spray directly onto cake
  5. Gently swirl until fully dissolved — do not shake vigorously
  6. Label with date, concentration, and diluent volume
  7. Refrigerate and use within your lab stability window

Typically reconstituted with 1–2 mL bacteriostatic water.

Laboratory record checklist

  • Compound identity recorded in lab notebook (name, lot, preparation date)
  • Analytical identity cross-checked against published sequence or structure
  • Potency or concentration documented from analytical certificate when available
  • Purity or HPLC data filed when provided with research material
  • Appearance noted: intact lyophilized cake or uniform powder
  • Sterility / endotoxin report archived when available
  • Storage temperature applied immediately per published stability guidance